CYCC
Cyclacel Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 6.76
- Prev close
- 6.37
- Mkt cap
- 2.05M
- Vol
- 219.91K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.10
- High
- 6.96
- Forward P/E
- -0.16
- Beta
- 0.56
- Short ratio
- 0.03
- Inst. own
- 18.03%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.5528
- 200-d avg
- 1.41
- 1y target
- 1.00
Key statistics
- Market cap
- 2.05M
- Enterprise value
- -5.19M
- Trailing P/E
- 0.00
- Forward P/E
- -0.16
- PEG ratio
- 0.00
- Price / sales
- 25.57
- Price / book
- 0.57
- EPS (TTM)
- -27.40
- Beta
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 80.00K
- Revenue growth
- -98.90%
- Free cash flow
- -7.66M
- Total cash
- 6.00M
- Total debt
- 5.00K
- Return on equity
- -570.69%
- Shares outstanding
- 6.29M
- Short % of float
- 3.23%
- 50-day average
- 0.5528
- 200-day average
- 1.41
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.29.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.54 | -0.18 | +0.36 | +66.67% |
| Aug 14, 2024 | Jun 1, 2024 | -0.83 | -0.72 | +0.11 | +13.25% |
| May 14, 2024 | Mar 1, 2024 | -4.93 | -2.27 | +2.66 | +53.96% |
| Mar 19, 2024 | Dec 1, 2023 | -6.35 | -6.23 | +0.12 | +1.89% |
| Nov 13, 2023 | Sep 1, 2023 | -5.70 | -7.35 | -1.65 | -28.95% |
| Aug 9, 2023 | Jun 1, 2023 | -8.10 | -6.60 | +1.50 | +18.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 3, 2024 | Roth MKM | main | Buy | Buy |
| Dec 19, 2023 | Brookline Capital | down | Buy | Hold |
| Dec 19, 2023 | Roth MKM | main | Buy | Buy |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cyclacel.com
News
- Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
- Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
- Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- Earnings Scheduled For May 15, 2025
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on CYCC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARKER SAMUEL L | Director | Stock Award(Grant) | Jun 29, 2023 | 40,415 |
| FERGUSON KENNETH M | Director | Stock Award(Grant) | Jun 29, 2023 | 44,952 |
| HENNEY CHRISTOPHER S | Director | Stock Award(Grant) | Jun 29, 2023 | 39,415 |
| KIRSCHBAUM MARK | Officer | Stock Award(Grant) | Jan 30, 2023 | 31,200 |
| MCBARRON PAUL | Chief Operating Officer | Purchase | Dec 20, 2023 | 33,378 |
| ROMBOTIS SPIRO GEORGE | Chief Executive Officer | Purchase | Dec 20, 2023 | 68,658 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 2.31% | 145,000 | 47.18K | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 0.24% | 15,333 | 4.99K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 0.23% | 14,285 | 4.65K | Sep 29, 2024 |
| UBS Group AG | 0.20% | 12,553 | 4.08K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.17% | 10,598 | 3.45K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 4,010 | 1.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.14% | 8,959 | 2.92K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.09% | 5,796 | 1.89K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 1,664 | 541 | Oct 30, 2024 |